Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON)

Clinical and Translational Oncology

Volumn 18, Issue 9, 2016, Pages 945-954

  Porta Sales, J ^a   Perez C ^b   Escobar, Y ^c   Martinez V ^d  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d Medical Manager Takeda   (Spain)

Author keywords

Breakthrough cancer pain; Cancer pain; Consensus; Delphi method; Pain

Indexed keywords

FENTANYL; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE;

ARTICLE; BREAKTHROUGH CANCER PAIN; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CONSENSUS; DELPHI STUDY; DRUG CONTRAINDICATION; FOLLOW UP; HUMAN; LIKERT SCALE; MEDICAL SPECIALIST; ORTHOSIS; PROFESSIONAL KNOWLEDGE; QUESTIONNAIRE; ANALGESIA; BREAKTHROUGH PAIN; ONCOLOGY; PROCEDURES; SPAIN;

BREAKTHROUGH PAIN; CANCER PAIN; CONSENSUS; DELPHI TECHNIQUE; HUMANS; MEDICAL ONCOLOGY; PAIN MANAGEMENT; SPAIN;

EID: 84951759257     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1468-7     Document Type: Article

References (50)

1. van den Everdingen MB, de Rijke J, Kessels A, Schouten H, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–49.
2. Vuorinen E. Pain as an early symptom in cancer. Clin J Pain. 1993;9(4):272–8.
3. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273–81.
4. Porta-Sales J, Rodríguez CG, Torras JJ, Merchán MC. Dolor irruptivo en cáncer. Med Clin. 2010;135(6):280–5.
5. Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014;47(1):57–76.
6. Fortner BV, Demarco G, Irving G, Ashley J, Keppler G, Chavez J, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003;25(1):9–18.
7. Gómez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M, et al. Breakthrough cancer pain. J Pain Symptom Manage. 2002;24(1):45–52.
8. Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med. 2001;15(1):9–18.
9. Greco MT, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone G. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients. Clin J Pain. 2011;27(1):9–18.
10. Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S. Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010;149(3):476–82.
11. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–68.
12. Davies AN, Dickman A, Reid C, Stevens A-M, Zeppetella G. The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331–8.
13. Zucco F, Bonezzi C, Fornasari D. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy. Adv Ther. 2014;31(7):657–82.
14. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. Pain. 1999;82(3):263–74.
15. Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W, et al. Breakthrough cancer pain: an observational study of 1000 european oncology patients. J Pain Symptom Manage. 2013;46(5):619–28.
16. Dickman A. Integrated strategies for the successful management of breakthrough cancer pain. Curr Opin Support Palliat Care. 2011;5(1):8–14.
17. Rustøen T, Geerling JI, Pappa T, Rundström C, Weisse I, Williams SC, et al. A European survey of oncology nurse breakthrough cancer pain practices. Eur J Oncol Nurs. 2013;17(1):95–100.
18. Webber K, Davies AN, Cowie MR. Accuracy of a diagnostic algorithm to diagnose breakthrough cancer pain as compared with clinical assessment. J Pain Symptom Manage. 2015. doi:10.1016/j.jpainsymman.2015.05.006.
19. Burton B, Zeppetella G. Assessing the impact of breakthrough cancer pain. Br J Nurs. 2011;20(Sup5):S14–9.
20. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3(1):38–44.
21. Fitch MI, McAndrew A, Burlein-Hall S. A Canadian online survey of oncology nurses’ perspectives on the management of breakthrough pain in cancer (BTPc). Can Oncol Nurs J. 2013;23(1):28–34.
22. Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12(10):1–8.
23. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008–15.
24. De Villiers MR, de Villiers PJT, Kent AP. The Delphi technique in health sciences education research. Med Teach. 2005;27(7):639–43.
25. Bernardo M, Bobes J, Sainz J. Consenso Delphi sobre la relevancia del manejo de la comorbilidad en el tratamiento del paciente con esquizofrenia. Sociedad Española de Psiquiatría y Sociedad Española de Psiquiatría biológica. Madrid, 2012, p. 72. http://www.1decada4.es/profsalud/estigma/Informe_Delphi_Esquizofrenia_y_Encuesta_Menphis.pdf.
26. Margarit C, Antón A, Escobar Y, Casas A, Cruz JJ, López R, et al. Breakthrough cancer pain—still a challenge. J Pain Res. 2012;5:559–66.
27. Elsner F, Zeppetella G, Porta-Sales J, Tagarro I. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. Clin Drug Investig. 2011;31(9):605–18.
28. Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, et al. Episodic (breakthrough) pain. Cancer. 2002;94(3):832–9.
29. Raj SX, Thronaes M, Brunelli C, Hjermstad MJ, Klepstad P, Kaasa S. A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. Support Care Cancer. 2014;22(7):1965–71.
30. Caraceni A, Davies A, Poulain P, Cortés-Funes H, Panchal SJ, Fanelli G. Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw. 2013;11(Suppl 1):S29–36.
31. Hagen NA, Stiles C, Nekolaichuk C, Biondo P, Carlson LE, Fisher K, et al. The Alberta breakthrough pain assessment tool for cancer patients: a validation study using a Delphi process and patient think-aloud interviews. J Pain Symptom Manage. 2008;35(2):136–52.
32. Webber K, Davies AN, Zeppetella G, Cowie MR. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manage. 2014;48(4):619–31.
33. Escobar Álvarez Y, Biete i Solà A, Camba Rodríguez M, Gálvez Mateos R, Mañas Rueda A, Rodríguez Sánchez CA, et al. Diagnóstico y tratamiento del dolor irruptivo oncológico: recomendaciones de consenso. Rev Soc Esp Dolor. 2013;20(2):61–8.
34. Virizuela JA, Escobar Y, Cassinello J, Borrega P. Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice. Clin Transl Oncol. 2012;14(7):499–504.
35. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii139–54.
36. Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B, Miaskowski C, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management. Pharm Ther. 2005;30(6):354–61.
37. William L, MacLeod R. Management of breakthrough pain in patients with cancer. Drugs. 2008;68(7):913–24.
38. Meriggi F, Zaniboni A. Fentanyl for breakthrough cancer pain: Where are we? Rev Recent Clin Trials. 2013;8(1):42–7.
39. Payne R, Coluzzi P, Hart L, Simmonds M, Lyss A, Rauck R, et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage. 2001;22(1):575–83.
40. ®). Pain. 2001;91(1):123–30.
41. Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84(5):587–93.
42. Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 1996. doi:10.1002/14651858.cd004311.pub3.
43. Soden K, Ali S, Alloway L, Barclay D, Barker S, Bird L, et al. How do nurses in specialist palliative care assess and manage breakthrough cancer pain? A multicentre study. Int J Palliat Nurs. 2013;19(11):528–34.
44. Wengström Y, Rundström C, Geerling J, Pappa T, Weisse I, Williams SC, et al. The management of breakthrough cancer pain—educational needs a European nursing survey. Eur J Cancer Care (Engl). 2013;23(1):121–8.
45. Soden K, Ali S, Alloway L, Barclay D, Perkins P, Barker S. How do nurses assess and manage breakthrough pain in specialist palliative care inpatient units? A multicentre study. Palliat Med. 2009;24(3):294–8.
46. Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther. 2000;17(2):70–83.
47. Núñez-Olarte JM, Álvarez-Jiménez P. Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain. J Pain Symptom Manage. 2011;42(6):e6–8.
48. Granata R, Bossi P, Bertulli R, Saita L. Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse. Pain Med. 2014;15(5):758–61.
49. Passik SD, Narayana A, Yang R. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain. Pain Med. 2014;15(8):1365–72.
50. Layton D, Osborne V, Al-Shukri M, Shakir SAW. Indicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk management. Drug Saf. 2014;37(8):639–50.